PT2229148E - Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina - Google Patents

Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina Download PDF

Info

Publication number
PT2229148E
PT2229148E PT88594122T PT08859412T PT2229148E PT 2229148 E PT2229148 E PT 2229148E PT 88594122 T PT88594122 T PT 88594122T PT 08859412 T PT08859412 T PT 08859412T PT 2229148 E PT2229148 E PT 2229148E
Authority
PT
Portugal
Prior art keywords
particulate
preparing
drug substance
crystalline drug
crystalline
Prior art date
Application number
PT88594122T
Other languages
English (en)
Inventor
Dilraj Singh
Gerhard Muhrer
Norbert Rasenack
Thomas Kieckbusch
Ranjit Thakur
Kurt Schaffluetzel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387173&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2229148(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2229148E publication Critical patent/PT2229148E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrrole Compounds (AREA)
PT88594122T 2007-12-13 2008-12-11 Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina PT2229148E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07123165 2007-12-13

Publications (1)

Publication Number Publication Date
PT2229148E true PT2229148E (pt) 2014-05-26

Family

ID=39387173

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88594122T PT2229148E (pt) 2007-12-13 2008-12-11 Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina

Country Status (13)

Country Link
US (1) US20100266696A1 (pt)
EP (1) EP2229148B1 (pt)
JP (1) JP2011506400A (pt)
KR (1) KR20100095587A (pt)
CN (1) CN101896165B (pt)
AU (1) AU2008334547B2 (pt)
BR (1) BRPI0820745A2 (pt)
CA (1) CA2707594C (pt)
ES (1) ES2460576T3 (pt)
PL (1) PL2229148T3 (pt)
PT (1) PT2229148E (pt)
RU (1) RU2496479C2 (pt)
WO (1) WO2009074666A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
SI2704724T1 (sl) * 2011-05-03 2017-01-31 Chiesi Farmaceutici S.P.A. Izboljšana formulacija suspenzije beklometazon dipropionata za dajanje z inhalacijo
GB201307659D0 (en) 2013-04-26 2013-06-12 Korea Coast Guard Commissioner Preparation of drug particles by micronisation
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
BR112017003888B1 (pt) 2014-09-09 2022-11-16 Vectura Limited Método de fabricação de uma formulação de pó seco
CN106749008A (zh) * 2015-11-23 2017-05-31 北京九和药业有限公司 一种马来酸茚达特罗的微粉化方法及其应用
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10888500B2 (en) 2016-07-29 2021-01-12 Inke, S.A. Particle size stabilization process

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20022674A1 (it) * 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
JP5138362B2 (ja) * 2004-03-23 2013-02-06 ノバルティス アーゲー 医薬組成物
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
EP1834624A4 (en) 2005-01-07 2011-05-04 Eisai R&D Man Co Ltd MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
RU2008108176A (ru) * 2005-08-26 2009-10-10 Астразенека Аб (Se) Комбинация соединений, которая может быть применена в лечении респеративных заболеваний, особенно хронического обструктивного заболевания легких (copd) и астмы
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations

Also Published As

Publication number Publication date
KR20100095587A (ko) 2010-08-31
BRPI0820745A2 (pt) 2015-06-16
CN101896165A (zh) 2010-11-24
PL2229148T3 (pl) 2014-08-29
US20100266696A1 (en) 2010-10-21
AU2008334547A1 (en) 2009-06-18
ES2460576T3 (es) 2014-05-13
EP2229148B1 (en) 2014-03-05
EP2229148A1 (en) 2010-09-22
JP2011506400A (ja) 2011-03-03
RU2010128248A (ru) 2012-01-20
AU2008334547B2 (en) 2011-06-30
CA2707594A1 (en) 2009-06-18
CN101896165B (zh) 2013-07-17
RU2496479C2 (ru) 2013-10-27
WO2009074666A1 (en) 2009-06-18
CA2707594C (en) 2015-08-18

Similar Documents

Publication Publication Date Title
PT2229148E (pt) Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina
IL205759A (en) History of isoxazolo-pyridine, a process for their preparation and the drugs containing them
HRP20160726T1 (hr) Soli piperazina i postupak za njihovu pripravu
EP2185159A4 (en) BORTEZOMIB AND MANUFACTURING METHOD THEREFOR
EP2234711A4 (en) PROCESS FOR PREPARING CRACKABLE CAPSULES FOR USE IN TOBACCO PRODUCTS
HK1158628A1 (en) Process for preparing dihydropteridinone derivatives
HK1160848A1 (en) Process for preparing chlorins and their pharmaceutical uses
EP2046751A4 (en) PROCESS FOR PRODUCING SOLIFENACIN AND ITS SALTS
IL205348A0 (en) Indolinone derivatives and process for their manufacture
ZA201101005B (en) A process for preparing a particulate filter
PL2213654T3 (pl) Sposób wytwarzania pochodnych 2-amino-5-bromobenzamidu
GB0614133D0 (en) Process for preparing a pharmaceutical compound
EP2318479A4 (en) METHOD AND SYSTEMS FOR THE PRODUCTION OF MATERIALS FOR SUCRALOSEPRODUCTION
GB0704335D0 (en) Process for preparing an encapsulated particulate solid
EP1898707A4 (en) PROCESS FOR THE PREPARATION OF MALATHION FOR PHARMACEUTICAL USE
HK1148228A1 (en) Method for preparing optionally substituted p-hydroxymandelic compounds and derivatives thereof
ZA200808308B (en) Process for preparing linezolid
GB0719248D0 (en) Compounds and methods for pharmaceutical use
EP2191848A4 (en) PRELIMINARY RELEASE PREPARATION AND METHOD OF MANUFACTURING THE SAME
ZA201201517B (en) A particulate fluorescer and a process for preparing the same
HUP0700757A2 (en) Process for producing pharmaceutical intermediers
EP2181109A4 (en) CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
GB0716298D0 (en) Process for pharmaceutical compound
GB0612695D0 (en) Process for preparing a solid dosage form
ZA200907810B (en) Process for preparing valsartan